съзн п вш н е  е враос ои еи с 7% о ихдоо еен тго р 39, 9% о пц етт.
Long-term olanzapine treatment (up to 12 months) for recurrence prevention in patients with bipolar disorder was associated with an increase of  from baseline body weight in 39.9% of 7% patients.